Literature DB >> 28394513

The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.

C Sophia Albott1,2,3, Paulo R Shiroma2,3, Kathryn R Cullen2, Brian Johns4, Paul Thuras3, Joseph Wels5, Kelvin O Lim2,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28394513     DOI： 10.4088/JCP.16l11277

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  9 in total

1.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches.

Authors:  Raquel Bennett; Christian Yavorsky; Gary Bravo
Journal:  Front Psychiatry       Date:  2022-05-23       Impact factor: 5.435

3.  Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study.

Authors:  Alina Wilkowska; Adam Włodarczyk; Maria Gałuszko-Węgielnik; Mariusz S Wiglusz; Wiesław J Cubała
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-14       Impact factor: 2.570

Review 4.  Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.

Authors:  Madison N Irwin; Amy VandenBerg
Journal:  Ment Health Clin       Date:  2021-05-12

Review 5.  Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.

Authors:  Sagar V Parikh; Daniela Lopez; Jennifer L Vande Voort; Jose Rico; Eric Achtyes; William Coryell; Andrew Goddard; Fernando Goes; John F Greden; Balwinder Singh; Adam Kaplin; Mark A Frye; Daniel Maixner; Brendon Watson; Karina Drake; Vijay Tarnal; Patricio Riva-Posse; William V Bobo
Journal:  Psychopharmacol Bull       Date:  2021-06-01

6.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

7.  Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use.

Authors:  Kazi Hassan; William M Struthers; Aditya Sankarabhotla; Patrick Davis
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

8.  Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.

Authors:  Bettina Diekamp; Stephane Borentain; Dong-Jing Fu; Robert Murray; Kristin Heerlein; Qiaoyi Zhang; Cornelius Schüle; Maju Mathews
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-15       Impact factor: 2.570

9.  Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.

Authors:  Jolien K E Veraart; Sanne Y Smith-Apeldoorn; Iris M Bakker; Berber A E Visser; Jeanine Kamphuis; Robert A Schoevers; Daan J Touw
Journal:  Int J Neuropsychopharmacol       Date:  2021-10-23       Impact factor: 5.176
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.